Sindilizumab Injection is indicated for the treatment of relapsed classical Hodgkin’s lymphoma and refractory classical Hodgkin’s lymphoma after second-line systemic chemotherapy. Sindilizumab Injection can also be used to treat people with altered epidermal growth factor receptor genes, as well as patients with advanced squamous non-small cell lung cancer. It is also effective in treating patients with cancers that cannot be directly removed by surgery. There will be some immunoglobulin in Sindilizumab injection, which can effectively produce antibodies in the body after use, and also kill the cancer cells in the body to produce some tumor immunity. Common adverse reactions include lung infection, anemia, elevated lipase, decreased platelet count, and pneumonia. Sindilizumab Injection is contraindicated in those who are allergic to the active ingredients or excipients. It is contraindicated in pregnant and lactating women. Sindilizumab Injection should be used under the guidance of a medical professional.